Tag Archives: Matthew Herder
Matthew Herder considers possible regulatory responses to the opioid epidemic that aim to recover health care costs, compensate survivors, or prosecute pharmaceutical companies.
Matthew Herder reviews three significant problems with the peer review system at CIHR, as a result of which high-quality research by social science and humanities researchers is left ‘undone.’
Matthew Herder shares a conversation with his mother about why she is a regular plasma donor.
Matthew Herder wrote a Master’s thesis on Canadian science policy some ten years ago and by the time he was done, he had sworn off the word ‘innovation.’
Matthew Herder shares a template letter that physicians, researchers, civil society groups, investigative journalists, and others can use to gain access to unpublished pharmaceutical safety and effectiveness data.
Matthew Herder and Trudo Lemmens explore the ways that Canada’s transparency legislation may limit researchers’ abilities to scrutinize drug safety and effectiveness.
Matthew Herder argues that recent drug price hikes are only one part of a bigger problem with industry-driven pharmaceutical research and development.